SCHEMBL4609052

SCHEMBL4609052

COC(=O)c1ccc(C(=O)Nc2ccc(C)c(C)c2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.69
NPC1 O15118 6/20 0.69
KMT2A Q03164 6/20 0.69
ATM Q13315 1/20 0.62
FKBP5 Q13451 1/20 0.61
CTDSP1 Q9GZU7 1/20 0.59
PTPN1 P18031 1/20 0.59
MEN1 O00255 4/20 0.57
MAPT P10636 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.56
KDM4E B2RXH2 2/20 0.55
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
ALDH1A1 P00352 1/20 0.55
TP53 P04637 1/20 0.55
PKM P14618 1/20 0.55
HPGD P15428 1/20 0.55
MAPK1 P28482 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4611508 0.90 NPC1 (0.68) RAB9ANPC1KMT2AATMPTPN1
SCHEMBL6781235 0.88 NPC1 (0.59) RAB9ANPC1KMT2AATMCTDSP1
SCHEMBL24891799 0.86 RAB9A (0.58) RAB9ANPC1KMT2AATMCTDSP1
SCHEMBL30182537 0.86 RAB9A (0.58) RAB9ANPC1KMT2AATMCTDSP1
SCHEMBL27905354 0.86 HDAC1 (0.58) RAB9ANPC1KMT2AATMCTDSP1
SCHEMBL6263819 0.85 PTPN1 (0.61) RAB9ANPC1KMT2AATMCTDSP1
SCHEMBL823156 0.84 RAB9A (0.75) RAB9ANPC1KMT2AFKBP5MEN1
SCHEMBL6263820 0.84 NPC1 (0.83) RAB9ANPC1KMT2AATMCTDSP1
SCHEMBL8660366 0.84 NPC1 (0.83) RAB9ANPC1KMT2AATMCTDSP1
SCHEMBL16589408 0.83 RAB9A (0.73) RAB9ANPC1KMT2AFKBP5MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1660437-B1 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF AMOREPACIFIC CORP (KR) 2008-10-15 EP disclosed
US-7282522-B2 Hydroxamic acid derivatives and the method for preparing thereof AMOREPACIFIC CORPORATION (KR) 2007-10-16 US disclosed
US-20060252834-A1 Hydroxamic acid derivatives and the method for preparing thereof AMOREPACIFIC CORPORATION (KR) 2006-11-09 US disclosed
EP-1660437-A4 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF AMOREPACIFIC CORP (KR) 2006-09-20 EP disclosed
EP-1660437-A1 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF Amorepacific Corporation (KR) 2006-05-31 EP disclosed
WO-2005019162-A1 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF AMOREPACIFIC CORPORATION (KR) 2005-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252834-A1 Hydroxamic acid derivatives and the method for preparing thereof HDAC7, SIRT7, HCAR1 RAB9A 4487/4885NPC1 2347/4885KMT2A 3483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.